Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in its pipeline
ProBioGen has announced Innovent Biologics, has signed a multi-product license for its GlymaxX technology.
Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in its pipeline. Therapeutic antibodies with low fucose content show a much higher antibody-dependent cellular cytotoxicity (ADCC) and therefore a higher killing activity against tumorigenic or infected cells.
ProBioGen claims its technology is universally applicable, simple, effective and can be integrated into cell lines of different origins. The technology also offers flexibility in terms of fucose level adjustment, since one cell line is sufficient to be used to produce both fucosylated and afucosylated antibodies.
Dr Gabriele Schneider, Chief Business Officer from ProBioGen stated: "We are very pleased to have Innovent as a new partner for a GlymaxX license. Since its foundation, Innovent has established itself in a very short time as an innovative biopharmaceutical company with its own fully-fledged antibody development platforms and a robust pipeline of antibodies. I am very much looking forward to this collaboration to benefit Innovent's products by the ease of use and high efficacy of our GlymaxX technology."